
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is well-positioned to capitalize on the growing demand for treatments for obesity and related conditions with their innovative use of AI and ML in developing precision antibodies. Their strong pipeline of potential therapies for obesity and cardiometabolic diseases, combined with promising results in preclinical and early human studies, give a positive outlook for the company's future success. However, investors should keep in mind the potential challenges of competition and the need for continued funding in the biotechnology industry.
Bears say
iBio is a biotechnology company that has a diverse pipeline of potential treatments for rare diseases, with its new drug IBIO-610 showing promise in treating obesity and other health issues. The company is also in a strong financial position, but faces risks in clinical trials and protecting its intellectual property. Future success will be determined by the results of these trials and regulatory approvals.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares